Article Information
History
- March 31, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jacob Kames1,
- David D. Holcomb1,
- Ofer Kimchi2,
- Michael DiCuccio3,
- Nobuko Hamasaki-Katagiri1,
- Tony Wang4,
- Anton A. Komar5,
- Aikaterini Alexaki1,* and
- Chava Kimchi-Sarfaty1,*
- 1Center for Biologics Evaluation and Research, Office of Tissues and Advanced Therapies, Division of Plasma Protein Therapeutics, Food and Drug Administration, Silver Spring, MD, USA
- 2Harvard University School of Engineering and Applied Sciences
- 3National Center of Biotechnology Information, National Institutes of Health, Bethesda, MD, USA
- 4Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, Division of Viral Products, Food and Drug Administration, Silver Spring, MD, USA
- 5Center for Gene Regulation in Health and Disease, Cleveland State University, Cleveland, OH, USA
- ↵*Corresponding authors: Chava Kimchi-Sarfaty, Ph.D.; Tel: +1 240 402-8203; Chava.kimchi-sarfaty{at}fda.hhs.gov; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, USA Correspondence may also be addressed to, Aikaterini Alexaki, Ph.D.; Tel: +1 240 402 7072; Aikaterini.alexaki{at}fda.hhs.gov; Division of Plasma Protein Therapeutics, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, USA
Posted March 31, 2020.
Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design
